Antimicrobial Use Among Hospitalized Patients: A Multi-Center, Point Prevalence Survey Across Public Healthcare Facilities, Osun State, Nigeria
Abstract
Introduction
Methods
Study design and settings
Inclusion and exclusion criteria
Data collection
Data analysis
Results
Demographical and clinical characteristics of patients
Bacteriological profiles
Prevalence and indication for antibiotic use in patients
Antibiotic prescribing across specialty wards
Antibiotic prescribing according to indications
Antibiotic prescribing according to WHO AWaRe classification
Discussion
Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- O’Neill, J. Review on antimicrobial resistance antimicrobial resistance: Tackling a crisis for the health and wealth of nations. London: Review on Antimicrobial Resistance. 2014. Available online: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pd.
- Resolution WHA 68-7. Global action plan on antimicrobial resistance. In Sixty-Eighth World Health Assembly; Geneva, 26 May 2015. Annex 3; World Health Organization: Geneva, 2015. [Google Scholar]
- A/RES/71/3; Political declaration of the high-level meeting of the General Assembly on antimicrobial resistance. United Nations: New York, 2016.
- National Action Plan for Antimicrobial Resistance (2017–2022). Available online: http://ncdc.gov.ng/themes/common/docs/protocols/7 7_1511368219.pdf (accessed on 04 December 2020).
- Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries. A practical toolkit. World Health Organization: Geneva, 2019.
- World Health Organization. WHO methodology for point prevalence survey on antibiotic use in hospitals, version 1.1. World Health Organization 2018. Available online: https://apps.who.int/iris/handle/10665/280063.
- Sharland, M.; Pulcini, C.; Harbarth, S.; et al. Classifying antibiotics in the WHO Essential Medicines List for optimal use-be AWaRe. Lancet Infect Dis. 2018, 18, 18–20. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Critically important antimicrobials for human medicine. 6th revision, 2019. Available online: https://www.who.int/foodsafety/publications/antimicr obials-sixth/en/.
- Uzochukwu, B.S.; Ughasoro, M.D.; Etiaba, E.; Okwuosa, C.; Envuladu, E.; Onwujekwe, O.E. Health care financing in Nigeria: Implications for achieving universal health coverage. Niger J Clin Pract. 2015, 18, 437–444. [Google Scholar] [CrossRef] [PubMed]
- Abubakar, U. Antibiotic use among hospitalized patients in northern Nigeria: A multicenter pointprevalence survey. BMC Infect Dis. 2020, 20, 86. [Google Scholar] [CrossRef] [PubMed]
- Umeokonkwo, C.D.; Madubueze, U.C.; Onah, C.K.; et al. Point prevalence survey of antimicrobial prescription in a tertiary hospital in South East Nigeria: A call for improved antibiotic stewardship. J Glob Antimicrob Resist. 2019, 17, 291–295. [Google Scholar] [CrossRef] [PubMed]
- Afriyie, D.K.; Sefah, I.A.; Sneddon, J.; et al. Antimicrobial point prevalence surveys in two Ghanaian hospitals: Opportunities for antimicrobial stewardship. JAC Antimicrob Resist. 2020, 2, dlaa001. [Google Scholar] [CrossRef] [PubMed]
- Atif, M.; Azeem, M.; Saqib, A.; Scahill, S. Investigation of antimicrobial use at a tertiary care hospital in Southern Punjab, Pakistan using WHO methodology. Antimicrob Resist Infect Control. 2017, 6, 41. [Google Scholar] [CrossRef] [PubMed]
- Denyer Willis, L.; Chandler, C. Quick fix for care, productivity, hygiene and inequality: Reframing the entrenched problem of antibiotic overuse. BMJ Glob Health. 2019, 4, e001590. [Google Scholar] [CrossRef] [PubMed]
- Cox, J.A.; Vlieghe, E.; Mendelson, M.; et al. Antibiotic stewardship in low- and middle-income countries: The same but different? Clin Microbiol Infect. 2017, 23, 812–818. [Google Scholar] [CrossRef] [PubMed]
- Vandael, E.; Latour, K.; Goossens, H.; et al. Point prevalence survey of antimicrobial use and healthcare-associated infections in Belgian acute care hospitals: Results of the Global-PPS and ECDC-PPS 201. Antimicrob Resist Infect Control. 2020, 9, 13. [Google Scholar] [CrossRef] [PubMed]
- Frenette, C.; Sperlea, D.; German, G.J.; et al. The 2017 global point prevalence survey of antimicrobial consumption and resistance in Canadian hospitals. Antimicrob Resist Infect Control. 2020, 9, 104. [Google Scholar] [CrossRef] [PubMed]
- Gandra, S.; Singh, S.K.; Jinka, D.R.; et al. Point prevalence surveys of antimicrobial use among hospitalized children in six hospitals in India in 2016. Antibiotics (Basel). 2017, 6, 19. [Google Scholar] [CrossRef] [PubMed]
- Momanyi, L.; Opanga, S.; Nyamu, D.; Oluka, M.; Kurdi, A.; Godman, B. Antibiotic prescribing patterns at a leading referral hospital in Kenya: A point prevalence survey. J Res Pharm Pract. 2019, 8, 149–154. [Google Scholar] [CrossRef] [PubMed]
- Saleem, Z.; Hassali, M.A.; Versporten, A.; et al. A multicenter point prevalence survey of antibiotic use in Punjab, Pakistan: Findings and implications. Expert Rev Anti Infect Ther. 2019, 17, 285–293. [Google Scholar] [CrossRef] [PubMed]
- Tarcea Bizo, P.; Dumitras, D.; Popa, A. Evaluation of restricted antibiotic use in a hospital in Romania. Int J Clin Pharm. 2015, 37, 452–456. [Google Scholar] [CrossRef] [PubMed]
- Okeke, I.N. Divining Without Seeds: The Case for Strengthening Laboratory Medicine in Africa; Culture and Politics of Health Care Work Book Series; Cornell University Press, 2011; 222 p. [Google Scholar] [CrossRef]
- Peters, D.H.; Garg, A.; Bloom, G.; Walker, D.G.; Brieger, W.R.; Rahman, M.H. Poverty and access to health care in developing countries. Ann N Y Acad Sci. 2008, 1136, 161–171. [Google Scholar] [CrossRef] [PubMed]
- Fadare, J.O.; Ogunleye, O.; Iliyasu, G.; et al. Status of antimicrobial stewardship programmes in Nigerian tertiary healthcare facilities: Findings and implications. J Glob Antimicrob Resist. 2019, 17, 132–136. [Google Scholar] [CrossRef] [PubMed]
- Horumpende, P.G.; Mshana, S.E.; Mouw, S.F.; Mmbaga, B.T.; Chilongola, J.O.; de Mast, Q. Point prevalence survey of antimicrobial use in three hospitals in North-Eastern Tanzania. Antimicrob Resist Infect Control. 2020, 9, 149. [Google Scholar] [CrossRef] [PubMed]
- Labi, A.K.; Obeng-Nkrumah, N.; Nartey, E.T.; et al. Antibiotic use in a tertiary healthcare facility in Ghana: A point prevalence survey. Antimicrob Resist Infect Control. 2018, 7, 15. [Google Scholar] [CrossRef] [PubMed]
- Frost, I.; Craig, J.; Joshi, J.; Faure, K.; Laxminarayan, R. Access Barriers to Antibiotics. Washington, DC: Center for Disease Dynamics, Economics & Policy; 2019. Available online: https://cddep.org/wp-content/uploads/2019/04/AccessBarrierstoAntibiotics_ CDDEP_FINAL.pdf.
- A technical guide to implementing the World Health Organization’s AWaRe antibiotic classification in MTaPS program countries. Available online: https://mtapsprogram.org/sites/default/files/USAID% 20MTaPS_Implementing%20WHO%20AWaRe%20Cl assification.pdf.
| Sociodemographic and clinical characteristics | n | % | |
|---|---|---|---|
| Gender (N=321) | Male | 142 | 43.9 |
| Female | 179 | 56.1 | |
| Surgery since admission (N=295): | Yes | 87 | 29.5 |
| No | 208 | 70.5 | |
| Diagnoses (N=250): | Skin and soft tissue infection | 20 | 8.0 |
| Bone and joint infection | 1 | 0.4 | |
| Central nervous system infection | 2 | 0.8 | |
| Ear, nose and throat infection | 2 | 0.8 | |
| Eye infection | 2 | 0.8 | |
| Respiratory tract infection | 18 | 7.2 | |
| Cardiovascular system infection | 2 | 0.8 | |
| Gastrointestinal tract infection | 15 | 6.0 | |
| Urinary tract infection | 6 | 2.4 | |
| Obstetrics and gynecological infection | 9 | 3.6 | |
| Clinical sepsis | 25 | 10.0 | |
| Systemic inflammatory response syndrome (SIRS) | 2 | 0.8 | |
| Undefined (site with no systemic inflammation) | 33 | 13.2 | |
| For use other than treatment | 113 | 45.2 | |
| Culture sample taking (N=260) | Yes | 38 | 14.6 |
| No | 222 | 85.4 | |
| Specimens collected (N=47)a | Sputum and respiratory specimen | 2 | 4.3 |
| Blood | 9 | 19.1 | |
| Sterile fluid | 9 | 19.1 | |
| Wound | 20 | 42.6 | |
| Urine | 6 | 12.8 | |
| Others | 1 | 2.1 | |
| Culture results (N=47): | Positive | 27 | 57.4 |
| Negative | 20 | 42.6 | |
| Bacterial isolated from specimens (N=38)b | Pseudomonas aeruginosa | 7 | 18.4 |
| Enterobacteriaceae* | 19 | 50.0 | |
| Staphylococcus aureus | 12 | 31.6 | |
| Resistant phenotypes (N=37) | Resistance to third generation cephalosporins | 14 | 37.8 |
| Carbapenem-resistant | 3 | 8.1 | |
| Methicillin-resistant S. aureus | 5 | 13.5 | |
| Unknown | 15 | 40.5 | |
| Antibiotic use | N | % | |
|---|---|---|---|
| Patients on antibiotics (N=321): | Yes | 246 | 76.6 |
| No | 75 | 23.4 | |
| Number of antibiotics used per patient (N=246)a: | 1 | 58 | 23.6 |
| 2 | 111 | 45.1 | |
| 3 | 46 | 18.7 | |
| 4 | 18 | 7.3 | |
| ≥5 | 13 | 5.3 | |
| Indication type (N=260): | Community-acquired infection | 76 | 29.2 |
| Hospital-acquired infection | 23 | 8.8 | |
| Surgical prophylaxis | 96 | 36.9 | |
| Medical prophylaxis | 29 | 11.2 | |
| Others | 36 | 13.8 | |
| Surgical prophylaxis duration (N=96): | SP1 | 1 | 1.0 |
| SP2 | 4 | 4.2 | |
| SP3 | 91 | 94.8 | |
| Antibiotic administration route (N=564): | Parenteral | 504 | 89.4 |
| Oral | 55 | 9.8 | |
| Inhalation | 5 | 0.9 | |
| Antibiotic switch from parenteral to oral (498): | Yes | 99 | 19.9 |
| No | 399 | 80.1 | |
| Prescriber type (N=564): | Specialist physicians | 497 | 88.1 |
| Non-specialist physician | 67 | 11.9 | |
| Missed doses of antibiotics (N=534): | None | 432 | 80.9 |
| 1 | 25 | 4.7 | |
| 2 | 22 | 4.1 | |
| ≥3 | 55 | 10.3 | |
| Reasons for missed doses (102): | Patient could not purchase | 96 | 94.1 |
| Other reasons | 2 | 2.0 | |
| Multiple reasons | 4 | 3.9 | |
| Guidelines compliance (561): | Yes | 221 | 39.4 |
| No | 201 | 35.8 | |
| Not assessable | 139 | 24.8 | |
| Treatment type: | Empiric | 544 | 96.6 |
| Directed | 19 | 3.4 |
| Antibiotics | Total wards, N (%) | AMW, n (%) | SW, n (%) | CW, n (%) | Ortho, n (%) | NNW/NICU, n (%) | Gyn, n (%) | ANW, n (%) | PNW, n (%) | MHW, n (%) | Ad ICU, n (%) | Burn, n (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amikacin | 1 (0.2) | 1 (1.9) | ||||||||||
| Gentamicin | 59 (10.5) | 5 (4.6) | 8 (6.2) | 10 (16.7) | 5 (9.6) | 22 (28.6) | 3 (7.9) | 4 (6.0) | 2 (10.5) | |||
| Amoxicillin | 7 (1.2) | 1 (0.9) | 2 (1.6) | 1 (1.7) | 2 (5.3) | 1 (1.5) | ||||||
| Amoxicillin/ clavulanate | 30 (5.3) | 14 (13.0) | 3 (2.3) | 3 (5.0) | 1 (1.3) | 3 (7.9) | 4 (6.0) | 2 (10.5) | ||||
| Ampicillin | 10 (1.8) | 8 (10.4) | 1 (20.0) | 1 (1.5) | ||||||||
| Ampicillin/ cloxacillin | 6 (1.1) | 3 (2.3) | 1 (1.7) | 2 (3.0) | ||||||||
| Penicillin | 2 (0.4) | 1 (0.9) | 1 (1.3) | |||||||||
| Cefuroxime | 104 (18.4) | 6 (5.6) | 27 (20.9) | 22 (36.7) | 17 (32.7) | 8 (10.4) | 3 (7.9) | 2 (40.0) | 16 (23.9) | 3 (15.8) | ||
| Cefixime | 7 (1.2) | 1 (0.9) | 3 (2.3) | 2 (3.0) | 1 (5.3) | |||||||
| Cefixime/ clavulanate | 1 (0.2) | 1 (2.6) | ||||||||||
| Cefotaxime | 2 (0.4) | 1 (0.8) | 1 (20.0) | |||||||||
| Ceftriaxone | 77 (13.7) | 19 (17.6) | 15 (11.6) | 9 (15.0) | 1 (1.9) | 14 (18.2) | 7 (18.4) | 8 (11.9) | 1 (20.0) | 3 (15.8) | ||
| Ceftriaxone/ sulbactam | 2 (0.4) | 1 (0.8) | 1 (2.6) | |||||||||
| Ceftazidime | 12 (2.1) | 2 (1.9) | 4 (3.1) | 2 (3.3) | 3 (3.9) | 1 (5.3) | ||||||
| Cefpodoxime | 5 (0.9) | 1 (0.8) | 2 (3.3) | 1 (1.5) | 1 (25.0) | |||||||
| Cefepime | 1 (0.2) | 1 (0.9) | ||||||||||
| Azithromycin | 7 (1.2) | 5 (4.6) | 1(1.7) | 1 (1.9) | ||||||||
| Erythromycin | 3 (0.5) | 2 (1.9) | 1 (0.8) | |||||||||
| Clarithromycin | 3 (0.5) | 2 (1.9) | 1 (2.6) | |||||||||
| Ciprofloxacin | 60 (10.6) | 13 (12.0) | 15 (11.6) | 3 (5.0) | 10 (19.2) | 10 (13.0) | 4 (10.5) | 1 (1.5) | 1 (25.0) | 1 (20.0) | 2 (10.5) | |
| Levofloxacin | 4 (0.7) | 2 (1.9) | 2 (1.6) | |||||||||
| Clindamycin | 2 (0.4) | 1 (0.8) | 1 (1.9) | |||||||||
| Imipenem | 1 (0.2) | 1 (5.3) | ||||||||||
| Meropenem | 4 (0.7) | 1 (0.9) | 2 (1.6) | 1 (1.3) | ||||||||
| Metronidazole | 142 (25.2) | 30 (27.8) | 40 (31.0) | 5 (8.3) | 15 (28.8) | 4 (5.2) | 13 (34.2) | 2 (40.0) | 26 (38.8) | 2 (50.0) | 2 (40.0) | 3 (15.8) |
| Nitrofurantoin | 2 (0.4) | 1 (0.9) | 1 (1.5) | |||||||||
| Doxycycline | 1 (0.2) | 1 (5.3) | ||||||||||
| Trimethoprim/ sulfamethoxazole | 1 (0.2) | 1 (0.9) | ||||||||||
| Vancomycin | 8 (1.4) | 1 (0.93) | 1 (1.7) | 1 (1.9) | 5 (6.5) | |||||||
| Total | 564 | 108 (19.1) | 129 (22.9) | 60 (10.6) | 52 (9.2) | 77 (13.7) | 38 (6.7) | 5 (0.9) | 67 (11.9) | 4 (0.7) | 5 (0.9) | 19 (3.4) |
| Antibiotics | CAI, n (%) | HAI, n (%) | SP, n (%) | MP, n (%) | Others, n (%) |
|---|---|---|---|---|---|
| Amikacin | 1 (0.6) | ||||
| Gentamicin | 19 (11.2) | 6 (14.3) | 14 (6.9) | 15 (22.1) | 3 (4.7) |
| Amoxicillin | 3 (1.8) | 1 (0.5) | 1 (1.5) | 2 (3.1) | |
| Amoxicillin/clavulanate | 12 (7.1) | 4 (9.5) | 7 (3.4) | 2 (2.9) | 4 (6.3) |
| Ampicillin | 1 (0.6) | 8 (11.8) | 1 (1.6) | ||
| Ampicillin/cloxacillin | 1 (0.6) | 2 (4.8) | 2 (1.0) | 1 (1.6) | |
| Penicillin | 1 (0.6) | 1 (1.6) | |||
| Cefuroxime | 27 (16.0) | 5 (11.9) | 52 (50) | 5 (7.4) | 13 (20.3) |
| Cefixime | 3 (1.8) | 2 (4.8) | 1 (0.5) | 1 (1.6) | |
| Cefixime/clavulanate | 1 (0.6) | ||||
| Cefotaxime | 2 (1.0) | ||||
| Ceftriaxone | 26 (15.4) | 3 (7.1) | 25 (12.6) | 11 (16.2) | 11 (17.2) |
| Ceftriaxone/sulbactam | 2 (1.0) | ||||
| Ceftazidime | 2 (1.2) | 3 (7.1) | 3 (1.5) | 3 (4.4) | 1 (1.6) |
| Cefpodoxime | 1 (0.6) | 2 (4.8) | 1 (0.5) | 1 (1.6) | |
| Cefepime | 1 (0.6) | ||||
| Azithromycin | 5 (3.0) | 2 (3.1) | |||
| Erythromycin | 3 (1.8) | ||||
| Clarithromycin | 3 (1.8) | ||||
| Ciprofloxacin | 13 (7.7) | 4 (9.5) | 22 (10.8) | 12 (17.6) | 6 (9.4) |
| Levofloxacin | 1 (0.6) | 2 (1.0) | 1 (1.6) | ||
| Clindamycin | 1 (0.6) | 1 (0.5) | |||
| Imipenem | 1 (2.4) | ||||
| Meropenem | 1 (0.6) | 1 (2.4) | 1 (0.5) | 1 (1.5) | |
| Metronidazole | 36 (21.3) | 7 (16.7) | 68 (33.3) | 7 (10.2) | 16 (25.0) |
| Nitrofurantoin | 2 (1.2) | ||||
| Doxycycline | 1 (2.4) | ||||
| Trimethoprim/sulfamethoxazole | 1 (0.6) | ||||
| Vancomycin | 4 (2.4) | 1 (2.4) | 3 (4.4) | ||
| Total | 169 (30.0) | 42 (7.4) | 204 (36.2) | 68 (12.1) | 64 (11.3) |
| Wards (N) | Access, n (%) | Watch, n (%) | Reserve, n (%) |
|---|---|---|---|
| Adult medical (108) | 52 (48.1) | 55 (50.9) | 1 (0.9) |
| Surgical (129) | 53 (41.1) | 76 (58.9) | 0 (0.0) |
| Children (60) | 19 (31.7) | 41 (68.3) | 0 (0.0) |
| Orthopedic (52) | 21 (40.4) | 31 (59.6) | 0 (0.0) |
| Neonatal (77) | 36 (46.8) | 41 (53.2) | 0 (0.0) |
| Gynecology (38) | 21 (55.3) | 17 (44.7) | 0 (0.0) |
| Postnatal (67) | 36 (53.7) | 31 (46.3) | 0 (0.0) |
| Burns (19) | 8 (42.1) | 11 (57.9) | 0 (0.0) |
| Antenatal (5) | 3 (60.0) | 2 (40.0) | 0 (0.0) |
| Mental health (4) | 2 (50.0) | 2 (50.0) | 0 (0.0) |
| Adult ICU (5) | 2 (40.0) | 3 (60.0) | 0 (0.0) |
| Total (564) | 261 (46.3) | 302 (53.5) | 1 (0.2) |
© 2021 by the authors.
Share and Cite
Aboderin, A.O.; Adeyemo, A.T.; Olayinka, A.A.; Oginni, A.S.; Adeyemo, A.T.; Oni, A.A.; Olabisi, O.F.; Fayomi, O.D.; Anuforo, A.C.; Egwuenu, A.; et al. Antimicrobial Use Among Hospitalized Patients: A Multi-Center, Point Prevalence Survey Across Public Healthcare Facilities, Osun State, Nigeria. GERMS 2021, 11, 523-535. https://doi.org/10.18683/germs.2021.1287
Aboderin AO, Adeyemo AT, Olayinka AA, Oginni AS, Adeyemo AT, Oni AA, Olabisi OF, Fayomi OD, Anuforo AC, Egwuenu A, et al. Antimicrobial Use Among Hospitalized Patients: A Multi-Center, Point Prevalence Survey Across Public Healthcare Facilities, Osun State, Nigeria. GERMS. 2021; 11(4):523-535. https://doi.org/10.18683/germs.2021.1287
Chicago/Turabian StyleAboderin, Aaron O., Adeyemi T. Adeyemo, Ademola A. Olayinka, Adeniyi S. Oginni, Abolaji T. Adeyemo, Abayomi A. Oni, Olatunde F. Olabisi, Oluwaseun D. Fayomi, Anthony C. Anuforo, Abiodun Egwuenu, and et al. 2021. "Antimicrobial Use Among Hospitalized Patients: A Multi-Center, Point Prevalence Survey Across Public Healthcare Facilities, Osun State, Nigeria" GERMS 11, no. 4: 523-535. https://doi.org/10.18683/germs.2021.1287
APA StyleAboderin, A. O., Adeyemo, A. T., Olayinka, A. A., Oginni, A. S., Adeyemo, A. T., Oni, A. A., Olabisi, O. F., Fayomi, O. D., Anuforo, A. C., Egwuenu, A., Hamzat, O., & Fuller, W. (2021). Antimicrobial Use Among Hospitalized Patients: A Multi-Center, Point Prevalence Survey Across Public Healthcare Facilities, Osun State, Nigeria. GERMS, 11(4), 523-535. https://doi.org/10.18683/germs.2021.1287
